Evidence map›Paper›PMID 31233733›Full record

ArticleExperimental and molecular pathology2019

Acute corneal injury in rabbits following nitrogen mustard ocular exposure.

Dinesh G Goswami, Rama Kant, David A Ammar, Dileep Kumar, Robert W Enzenauer, J Mark Petrash, Neera Tewari-Singh, Rajesh Agarwal

Open access · greenAbstract read
In one paragraph

Article in Experimental and molecular pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. BRD4 inhibition mitigates acute and chronic corneal injury following topical nitrogen mustard exposure.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Dinesh G GoswamiDepartment of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
Rama KantDepartment of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
David A AmmarDepartment of Ophthalmology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
Dileep KumarDepartment of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
Robert W EnzenauerDepartment of Ophthalmology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
J Mark PetrashDepartment of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA; Department of Ophthalmology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
Neera Tewari-SinghDepartment of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
Rajesh AgarwalDepartment of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA. Electronic address: Rajesh.Agarwal@ucdenver.edu.
University of Colorado Anschutz Medical Campus · US

Funding

Effective Therapies for Ocular Injuries by Vesicating AgentsU01EY023143 · NEI · UNIVERSITY OF COLORADO DENVER · PI AGARWAL, RAJESH · 2012 to 2016
$3.9M
NEI NIH HHS U01 EY023143
6 · The paper itself

Abstract

Sulfur mustard (SM), a potent vesicating chemical warfare agent, and its analog nitrogen mustard (NM), are both strong bi-functional alkylating agents. Eyes, skin, and the respiratory system are the main targets of SM and NM exposure; however, ocular tissue is most sensitive, resulting in severe ocular injury. The mechanism of ocular injury from vesicating agents' exposure is not completely understood. To understand the injury mechanism from exposure to vesicating agents, NM has been previously employed in our toxicity studies on primary human corneal epithelial cells and ex vivo rabbit cornea organ culture model. In the current study, corneal toxicity from NM ocular exposure (1%) was analyzed for up to 28 days post-exposure in New Zealand White male rabbits to develop an acute corneal injury model. NM exposure led to conjunctival and eyelid swelling within a few hours after exposure, in addition to significant corneal opacity and ulceration. An increase in total corneal thickness and epithelial degradation was observed starting at day 3 post-NM exposure, which was maximal at day 14 post-exposure and did not resolve until 28 days post-exposure. There was an NM-induced increase in the number of blood vessels and inflammatory cells, and a decrease in keratocytes in the corneal stroma. NM exposure resulted in increased expression levels of cyclooxygenase-2, Interleukin-8, vascular endothelial growth factor and Matrix Metalloproteinase 9 indicating their involvement in NM-induced corneal injury. These clinical, biological, and molecular markers could be useful for the evaluation of acute corneal injury and to screen for therapies against NM- and SM-induced ocular injury.

Indexed as

Acute DiseaseAnimalsChemical Warfare AgentsCorneaCorneal InjuriesCyclooxygenase 2HumansImmunohistochemistryInterleukin-8MaleMatrix Metalloproteinase 9MechlorethamineMustard GasRabbitsVascular Endothelial Growth Factor AChemical Warfare AgentsCyclooxygenase 2Interleukin-8Matrix Metalloproteinase 9MechlorethamineMustard GasVascular Endothelial Growth Factor ACorneal injuryInflammationMustardNitrogen mustardSulfur mustardVesicant

Identifiers

PMID31233733
PMCPMC6754274
OpenAlexW2951886734

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.